NGS
Disease-Focused Next Generation Sequencing (NGS)
Testing for somatic (acquired) gene mutations can help better understand a range of blood and solid tumor cancers. While insights continue to uncover new gene associations and their impact across the continuum of patient care, especially in treatment selection, siParadigm provides panels that deliver the most actionable and relevant information for clinicians.
SOLID TUMOR PANELS (TISSUE AND LIQUID SAMPLES)
TEST DESCRIPTIONS: (BIOMARKERS ANALYZED BY TUMOR TYPE)
*Gene is also included in the RNA gene-fusion panel.
BLADDER CANCERS
Bladder Multi-Omics™
MSI and TMB
*ALK, AKT1, *AR, ATM, BAP1, *BRAF, BRCA1, BRCA2, CDKN2A, CCND1, CREBBP, *EGFR, ERBB2, ERBB3, ERBB4, FANCA, FBXW7, *FGFR1, *FGFR2, *FGFR3, HRAS, KDM6A, KMT2A, KMT2C, KMT2D, KRAS, MAP2K1, NF1, NRAS, PIK3CA, PTEN, RB1, *RET, SMARCA4, STAG2, TERT, TP53.
BRAIN/CNS CANCERS
Brain Multi-Omics™
MSI and TMB
APC, ATRX, BRAF, CDK4, CTNNB1, CDKN2A, CDKN2B, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, H3F3A, HRAS, IDH1, IDH2, NRG1, KIT, KRAS, MET, MTOR, MYCN, MYD88, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, TP53, TSC1,TSC2.
BREAST CANCERS
Breast Multi-Omics™
TMB, MSI and HRD for PARPi efficacy
*AR, AKT1, ATM, *BRAF, BRCA1, BRCA2, CCNE1, CDH1, CDK12, CHEK1, CHEK2, *EGFR, ERBB2, ERBB3, ERBB4, *ESR1, FANCA, FANCL, *FGFR1, *FGFR2, *FGFR3, KRAS, MLH1, MRE11A, MSH2, MSH6, MUTYH, MYC, NBN, *NTRK1, *NTRK2, *NTRK3, PALB2, PIK3CA, PMS2, PTEN, RAD50, RAD51, RB1, *RET, STK11, TERT, TP53.
COLORECTAL CANCERS
Colorectal Multi-Omics™
MSI and TMB
AKT1, APC, ATM, AXIN2, *BRAF, CHEK1, CHEK2, ERBB2, ERBB3, ERBB4, *EGFR, FANCA, FBXW7, HRAS, KRAS, MAP2K1, *MET, MLH1, MSH2, MSH6, MUTYH, *NTRK1, *NTRK2, *NTRK3, NRAS, PIK3CA, PMS2, POLD1, POLE, PTEN, *RET, SMAD4, STK11, TERT, TP53.
ENDOMETRIAL CANCERS
Endometrial Multi-Omics™
MSI and TMB
AKT1, APC, ARID1A, ARID2, ATM, *BRAF, BRCA1, BRCA2, CDK12, CDK4, CHEK2, CTNNB1, EPCAM, ERBB2, *ESR1, FBXW7, KRAS, MDM2, MLH1, MSH2, MSH6, NBN, NRAS, *NTRK1, *NTRK2, *NTRK3, PALB2, PIK3CA, PMS2, POLE, POLD1, PPP2R1A, PTEN, *RET, RNF43, SAMD4, STK11, TP53.
ESOPHAGEAL CANCERS
Esophagus Multi-Omics™
MSI and TMB
AKT1, *AR, ARAF, ARID1A, *BRAF, CDK12, CDK6, CCNE1, CCND1, CDKN2A, *EGFR, ERBB2, ERBB3, *FGFR1, *FGFR2, *FGFR3, KIT, KRAS, MCL1, MAP2K1, *MET, MLH1, MSH2, MSH6, MTOR, *NTRK1, *NTRK2, *NTRK3, *NRG1, NRAS, PMS2, PIK3CA, *RET, TP53.
GASTRIC/GIST CANCERS
Gastric/GIST Multi-Omics™
MSI and TMB
*AR, APC, ATM, *BRAF, CD274, CDH1, CCNE1, CTNNB1, ERBB2, ERBB4, *EGFR, FBXW7.*FGFR1, *FGFR2, *FGFR3, KRAS, *MET, MDM2, MEN1, MLH1, MSH2, MSH6, NF1, *NRG1, NRAS, *NTRK1, *NTRK2, *NTRK3, PDGFRA, PIK3CA, PMS2, PTEN, *RET, RB1, SAMD4, SDHA, SDHB, SDHC, SDHD, TP53.
HEAD AND NECK CANCERS
Head and Neck Multi-Omics™
MSI and TMB
*AR, ATM, ARAF, *BRAF, CD274, CDKN2A, *EGFR, ERBB2, ERBB3, *FGFR1, *FGFR2, *FGFR3, HRAS, IDH1, IDH2, KRAS, *MET, MTOR, MLH1, MSH2, MSH6, NOTCH1, NRAS, *NRG1, *NTRK1, *NTRK2, *NTRK3, PIK3CA, PMS2, PTEN, *RSPO2,*RET, TERT, TP53.
HEPATOCELLULAR & BILIARY TRACT CANCERS
Liver Multi-Omics™
MSI and TMB
AKT1, ARAF, ARID1A, ATM, *BRAF, BAP1, BRCA1, BRCA2, CTNNB1, *EGFR, ERBB2, ERBB3, ERBB4, *ESR1, *FGFR1, *FGFR2, *FGFR3, FGFR4, GNA11, IDH1, IDH2, KIT, KRAS, MAP2K1, MAP2K2, *MET, MLH1, MSH2, MSH6, MTOR, NRAS, *NRG1, *NTRK1, *NTRK2, *NTRK3, PALB2, PIK3CA, PMS2, PTEN, *RET, RAD51D, TERT, TP53.
LUNG CANCERS
Lung Multi-Omics™
MSI and TMB
AKT1, *ALK, ARAF, ATM, *BRAF, ARID2, CCND1, CD274, CDK4, CDKN2A, CHEK2, ERBB2, ERBB3, *EGFR, *FGFR1, *FGFR2, *FGFR3, HRAS, KEAP1, KRAS, MAP2K1, *MET, MYCL, MTOR, NFE2L2, *NRG1, NRAS, *NTRK1, *NTRK2, *NTRK3, *NUTM1, PIK3CA, *RET, RICTOR, *ROS1, RB1, STK11, TP53.
MELANOMA
Melanoma Multi-Omics™
MSI and TMB
APC, ARID2, ATM, *BRAF, BAP1, BRCA2, CCND1, CDK4, CDKN2A, CHEK2, CTNNB1, EIF1AX, FBXW7, GNA11, GNAQ, GNAS, IDH1, KIT, MAP2K1, MAP2K2, NF1, NRAS, *NTRK1, *NTRK2, *NTRK3, PALB2, PDGFRA, PIK3CA, PTEN, RB1, *RET, *ROS1, SF3B1, SMO, SRC, TERT, TP53.
OVARIAN CANCERS
Ovarian Multi-Omics™
TMB, MSI and HRD for PARPi efficacy
AKT1, ARAF, ATM, ARID1A, BARD1, *BRAF, BRCA1, BRCA2, BRIP1, CCNE1, CDK12, CHEK1, CHEK2, CTNNB1, ERBB2, *ESR1, FANCA, FANCL, *FGFR1, *FGFR2, *FGFR3, FOLR1, KIT, MAP2K1, *MET, MLH1, MSH2, MSH6, MTOR, *NTRK1, *NTRK2, *NTRK3, NF1, *NRG1, PALB2, PIK3CA, PMS2, PPP2R1A, PTEN, RAD51C, RAD51D, RAD54L, RET, TP53.
PANCREATIC CANCERS
Pancreas Multi-Omics™
TMB, MSI and HRD for PARPi efficacy
*ALK, ATM, *BRAF, BRCA1, BRCA2, CDKN2A, ERBB2, *FGFR1, *FGFR2, *FGFR3, FANCL, IDH1, IDH2, KRAS, MLH1, MSH2, MSH6, *NRG1, *NTRK1, *NTRK2, *NTRK3, PALB2, PMS2, PIK3CA, *RET, *ROS1, SMAD4, STK11, TP53.
PROSTATE CANCERS
Prostate Multi-Omics™
TMB, MSI and HRD for PARPi efficacy
AKT1, *AR, ARID1A, ATM, ATR, BARD1, *BRAF, BRCA1, BRCA2, BRIP1, CCND1, CDK12, CHEK1, CHEK2, CTNNB1, FANCA, FANCD2, FANCL, HRAS, IDH1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, *NTRK1, *NTRK2, *NTRK3, PALB2, PIK3CA, PMS2, PPP2R2A, PTEN, RAD51B, RAD51C, RAD51D, RB1, *RET, SPOP, TERT, TP53.
THYROID CANCERS
Thyroid Multi-Omics™
MSI and TMB
*ALK, AKT1, *BRAF, BRCA1, BRCA2, CDKN2A, CTNNB1, *FGFR1, *FGFR2, *FGFR3, HRAS, IDH1, IDH2, KRAS, MET, *NTRK1, *NTRK2, *NTRK3, NRAS, *RET, MLH1, MSH2, MSH6, PMS2, PALB2, PIK3CA, PTEN, TERT.
TUMOR OF UNKNOWN ORIGIN AND OTHERS
Unknown Origin Multi-Omics™
MSI and TMB
AKT1, ALK, AR, ARAF, BRAF, CD274, CDK4, CDKN2A, CHEK2, CTNNB1, EGFR, ERBB2, ERBB3, ERBB4, ERG, ESR1, ETV1, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PIK3CA, PTEN, RAF1, RET, ROS1, SMO, TP53
Hereditary Cancer Specific Gene Panels
BRCA1/BRCA2
BRCA1/BRCA2 full gene sequencing and deletion/duplication analysis
Lynch Syndrome & Hereditary Colon Cancer
18-Gene panel including: APC, AXIN2, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH3, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53)
Breast and Ovarian Cancer
18-Gene panel including: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MRE11A, MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53
Pancreatic Cancer
19-Gene panel including: APC, ATM, BRCA1, BRCA2, BMPR1A, CDK4, CDKN2A, EPCAM, MEN1, MLH1, MSH2, MSH6, NF1, PALB2, PMS2 , SMAD4, STK11, TP53, VHL
Prostate Cancer
15-Gene panel including: ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53
Comprehensive panel (Individual Genes Available Upon Request)
45-Gene panel including: APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRIP1, BRCA1, BRCA2, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, ERCC2, KIT, MEN1, MITF, MLH1, MRE11A, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, PALB2, PDGFRA, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, VHL
The comprehensive panel is intended for patients with a personal or family history of multiple qualifying cancers. By selecting this panel, the ordering physician attests that testing is medically necessary and that the patient’s personal or family history meets the criteria.
For New York Approved Gene List, Please Visit Our Website: www.neovare.com/en/our-tests
Hematology Panels
Myeloid Focused, DNA
Myeloid Comprehensive, DNA
AML/Eosinophilia, DNA/RNA
Lymphoid
"While we have many laboratories to choose from, we consider siParadigm to be the most reliable. Contact with a hematopatholgist is rapid and informative."
Barry Kaplan, MD, PhD
Oncologist/Hematologist, Queens Medical Assoc.
Discover more.
A Model Experience
With core values rooted in service and integrity, our leadership team sets the bar high.
We consistently strive to set the model for exactly how a reference laboratory should engage with both physicians and patients.
Accredited and Certified
siParadigm is accredited by CLIA (Clinical Laboratory Improvement Amendments) and certified by CAP (College of American Pathologists).
We also hold select state licensure where required.
Contact Us
+1 888 599 LABS
Customer Service
cs@siparadigm.com
Have Questions or Concerns?
feedback@siparadigm.com
Careers
careers@siparadigm.com
Billing Inquiries
fap.billing@siparadigm.com
Unless otherwise noted, all content is CC-BY 2020 by siParadigm, LLC.